Ratings DocGo Inc.

Equities

DCGO

US2560861096

Real-time Estimate Cboe BZX Other stock markets 10:23:35 2024-05-21 am EDT			5-day change	1st Jan Change
3.025 ^USD	-0.49%		-8.18%	-45.80%

May. 09	Cantor Fitzgerald Adjusts DocGo Price Target to $5 From $11, Maintains Overweight Rating	MT
May. 09	Deutsche Bank Adjusts DocGo Price Target to $5 From $8.20, Maintains Buy Rating	MT

Strengths

The company's profit outlook over the next few years is a strong asset.
The company is in a robust financial situation considering its net cash and margin position.
The stock, which is currently worth 2024 to 0.34 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DOCGO INC.	-45.80%	309M		-
AMEDISYS, INC.	+1.18%	3.14B		B-
BRIGHTSPRING HEALTH SERVICES, INC.	0.00%	1.96B		-
ADDUS HOMECARE CORPORATION	+19.04%	1.79B		C
THE PENNANT GROUP, INC.	+68.75%	695M		D+
BASTIDE LE CONFORT MÉDICAL	-20.34%	170M		-
SAINT-CARE HOLDING CORPORATION	-15.65%	134M		-
KATO (HONG KONG) HOLDINGS LIMITED	+3.85%	67.96M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes